ABBV vs. PHG: A Head-to-Head Stock Comparison

Updated on October 9, 2025

Here’s a clear look at ABBV and PHG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

ABBV is a standard domestic stock, while PHG trades as New York Registered Shares, providing U.S. investors with a way to invest in the foreign-based company.

Symbol	ABBV	PHG
Company Name	AbbVie Inc.	Koninklijke Philips N.V.
Country	United States	Netherlands
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Health Care Equipment & Supplies
Market Capitalization	406.64 billion USD	26.65 billion USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	March 17, 1980
Security Type	Common Stock	NY Reg Shrs

Historical Performance

This chart compares the performance of ABBV and PHG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. PHG: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	PHG
5-Day Price Return	-0.58%	3.74%
13-Week Price Return	22.68%	16.38%
26-Week Price Return	11.60%	3.74%
52-Week Price Return	17.77%	-18.89%
Month-to-Date Return	-0.58%	3.60%
Year-to-Date Return	29.54%	-2.17%
10-Day Avg. Volume	7.35M	1.24M
3-Month Avg. Volume	5.73M	1.56M
3-Month Volatility	24.02%	25.90%
Beta	0.36	1.09

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

PHG

-0.18%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABBV vs. PHG: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

PHG

0.90%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

ABBV vs. PHG: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

PHG

6.11%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

ABBV vs. PHG: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	ABBV	PHG
Return on Equity (TTM)	95.59%	-0.18%
Return on Assets (TTM)	2.73%	-0.08%
Net Profit Margin (TTM)	6.45%	0.90%
Operating Profit Margin (TTM)	18.80%	6.11%
Gross Profit Margin (TTM)	70.93%	43.85%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

PHG

1.26

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ABBV vs. PHG: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

PHG

0.81

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

ABBV vs. PHG: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

PHG

1.41

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

ABBV vs. PHG: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	PHG
Current Ratio (MRQ)	0.74	1.26
Quick Ratio (MRQ)	0.48	0.81
Debt-to-Equity Ratio (MRQ)	49.22	0.81
Interest Coverage Ratio (TTM)	2.70	1.41

Growth

Revenue Growth

ABBV vs. PHG: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. PHG: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.74%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.74% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

PHG

0.00%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

ABBV vs. PHG: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

PHG

0.42%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ABBV vs. PHG: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	ABBV	PHG
Dividend Yield (TTM)	2.74%	0.00%
Dividend Payout Ratio (TTM)	226.84%	0.42%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

109.81

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 109.81, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

PHG

140.93

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

At 140.93, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

ABBV vs. PHG: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.08

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.08 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PHG

1.27

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.27 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ABBV vs. PHG: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

PHG

1.89

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ABBV vs. PHG: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	ABBV	PHG
Price-to-Earnings Ratio (TTM)	109.81	140.93
Price-to-Sales Ratio (TTM)	7.08	1.27
Price-to-Book Ratio (MRQ)	261.01	1.89
Price-to-Free Cash Flow Ratio (TTM)	22.66	14.75